Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies

Aims: Evofosfamide (TH-302) is a hypoxia-activated prodrug (HAP) that releases the DNA-damaging bromo-isophosphoramide mustard (Br-IPM) moiety selectively under hypoxic conditions. Since solid tumors are known to have hypoxic regions, HAPs in combination with chemotherapy or radiotherapy (XRT) will...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antioxid Redox Signal
Auteurs principaux: Takakusagi, Yoichi, Kishimoto, Shun, Naz, Sarwat, Matsumoto, Shingo, Saito, Keita, Hart, Charles P., Mitchell, James B., Krishna, Murali C.
Format: Artigo
Langue:Inglês
Publié: Mary Ann Liebert, Inc. 2018
Sujets:
Original Research Communications
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5725636/
https://ncbi.nlm.nih.gov/pubmed/28741367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/ars.2017.7106
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires